Taniguchi Tomohiro, Tsuha Sanefumi, Shiiki Soichi, Narita Masashi
Division of Infectious Diseases, Okinawa Chubu Hospital, 281 Miyazato, Uruma, Okinawa, 904-2293, Japan.
BMC Infect Dis. 2015 Oct 26;15:458. doi: 10.1186/s12879-015-1203-6.
The Gram stain has been used as an essential tool for antimicrobial stewardship in our hospital since the 1970s. The objective of this study was to clarify the difference in the targeted therapies selected based on the Gram stain and simulated empirical therapies based on the antimicrobial guidelines used in Japan.
A referral-hospital-based prospective descriptive study was undertaken between May 2013 and April 2014 in Okinawa, Japan. All enrolled patients were adults who had been admitted to the Division of Infectious Diseases through the emergency room with suspected bacterial infection at one of three sites: respiratory system, urinary tract, or skin and soft tissues. The study outcomes were the types and effectiveness of the antibiotics initially selected, and their total costs.
Two hundred eight patients were enrolled in the study. The median age was 80 years. A significantly narrower spectrum of antibiotics was selected based on the Gram stain than was selected based on the Japanese guidelines. The treatments based on the Gram stain and on the guidelines were estimated to be equally highly effective. The total cost of antimicrobials after Gram-stain testing was less than half the cost after the guidelines were followed.
Compared with the Japanese guidelines, the Gram stain dramatically reduced the overuse of broad-spectrum antimicrobials without affecting the effectiveness of the treatment. Drug costs were reduced by half when the Gram stain was used. The Gram stain should be included in all antimicrobial stewardship programs.
自20世纪70年代以来,革兰氏染色一直是我院抗菌药物管理的重要工具。本研究的目的是阐明基于革兰氏染色选择的靶向治疗与基于日本使用的抗菌指南模拟的经验性治疗之间的差异。
2013年5月至2014年4月在日本冲绳进行了一项基于转诊医院的前瞻性描述性研究。所有入选患者均为成年人,他们通过急诊室被收治入传染病科,怀疑在三个部位之一存在细菌感染:呼吸系统、泌尿系统或皮肤及软组织。研究结果是最初选择的抗生素的类型和有效性及其总成本。
208名患者纳入研究。中位年龄为80岁。基于革兰氏染色选择的抗生素谱明显比基于日本指南选择的窄。基于革兰氏染色和基于指南的治疗估计同样高效。革兰氏染色检测后抗菌药物的总成本不到遵循指南后的一半。
与日本指南相比,革兰氏染色显著减少了广谱抗菌药物的过度使用,而不影响治疗效果。使用革兰氏染色时,药物成本降低了一半。所有抗菌药物管理计划都应纳入革兰氏染色。